|
EP0992506B1
(en)
*
|
1998-10-08 |
2003-08-06 |
Novartis AG |
Process for the sulfurisation of phosphorus-containing compounds
|
|
US7098325B2
(en)
*
|
1998-10-08 |
2006-08-29 |
Pierre Martin |
Process for the sulfurization of a phosphorus-containing compound
|
|
GB0004889D0
(en)
|
2000-03-01 |
2000-04-19 |
Avecia Ltd |
Synthesis of oligonucleotides
|
|
AU2002220870A1
(en)
*
|
2000-12-05 |
2002-06-18 |
Avecia Limited |
Process for the preparation of phosphorothionate oligonucleotides
|
|
US6768005B2
(en)
*
|
2000-12-20 |
2004-07-27 |
Avecia Limited |
Process
|
|
AR036122A1
(es)
*
|
2001-07-03 |
2004-08-11 |
Avecia Biotechnology Inc |
Un complejo de sal que comprende un n-alquilimidazol y una 1,1-dioxo-1,2-dihidro-1l6-benzo [d]-isotiazol-3-ona y un metodo para sintetizar oligonucleotidos utilizando la quimica de fosforamidita
|
|
JP4825375B2
(ja)
*
|
2001-08-28 |
2011-11-30 |
株式会社 資生堂 |
ジチアゾール化合物及びマトリックスメタロプロテアーゼ活性阻害剤、皮膚外用剤
|
|
GB0209539D0
(en)
*
|
2002-04-26 |
2002-06-05 |
Avecia Ltd |
Monomer Polymer and process
|
|
EP2540734B1
(en)
*
|
2004-04-05 |
2016-03-30 |
Alnylam Pharmaceuticals, Inc. |
Process and reagents for oligonucleotide synthesis and purification
|
|
CN104086516B
(zh)
*
|
2014-07-18 |
2016-01-06 |
成都樵枫科技发展有限公司 |
R-(+)-硫代四氢呋喃-2-甲酸的合成方法
|
|
KR20190100225A
(ko)
|
2016-12-28 |
2019-08-28 |
다이이찌 산쿄 가부시키가이샤 |
알포트 증후군 치료약
|
|
WO2019111791A1
(ja)
*
|
2017-12-07 |
2019-06-13 |
第一三共株式会社 |
ジストロフィン遺伝子のイントロンリテンションを解消するアンチセンスオリゴヌクレオチド
|
|
WO2019172286A1
(ja)
|
2018-03-09 |
2019-09-12 |
第一三共株式会社 |
糖原病Ia型治療薬
|
|
CA3102236A1
(en)
|
2018-06-13 |
2019-12-19 |
Daiichi Sankyo Company, Limited |
Myocardial dysfunction therapeutic agent
|
|
US20230061732A1
(en)
|
2019-06-05 |
2023-03-02 |
Fukuoka University |
Stable target-editing guide rna having chemically modified nucleic acid introduced thereinto
|
|
EP3995153A4
(en)
|
2019-06-26 |
2023-11-22 |
KNC Laboratories Co., Ltd. |
Nucleic acid drug suppressing production of myostatin gene mrna
|
|
JP7627495B2
(ja)
|
2019-07-12 |
2025-02-06 |
学校法人東海大学 |
DUX4 pre-mRNAのスプライシングを変化させるアンチセンスオリゴヌクレオチド
|
|
IL291251B2
(en)
|
2019-09-10 |
2026-06-01 |
Daiichi Sankyo Co Limited |
CONJUGATE OF GalNAC-OLIGONUCLEOTIDE FOR DELIVERY TO LIVER AND MANUFACTURING METHOD THEREOF
|
|
EP4047005A4
(en)
|
2019-10-18 |
2024-03-06 |
Daiichi Sankyo Company, Limited |
PROCESS FOR MANUFACTURING BICYCLIC PHOSPHORAMIDITE
|
|
EP4119167A4
(en)
|
2020-03-11 |
2025-08-06 |
Biocomber Co Ltd |
SINGLE-STRANDED NUCLEIC ACID MOLECULE FOR INDUCING FRAME SHIFT-1 AND COMPOSITION
|
|
WO2022024833A1
(ja)
|
2020-07-28 |
2022-02-03 |
神戸天然物化学株式会社 |
アンギオテンシン変換酵素2遺伝子のエクソンのスキッピングを誘導するアンチセンス核酸
|
|
MX2023006714A
(es)
|
2020-12-08 |
2023-07-13 |
Univ Fukuoka |
Acido ribonucleico (arn) guia estable de edicion de objetivo al cual se introduce acido nucleico quimicamente modificado.
|
|
US20240229036A9
(en)
|
2021-02-26 |
2024-07-11 |
Knc Laboratories Co., Ltd. |
Nucleic acid medicine expressing splicing variant of myostatin
|
|
IL315659A
(en)
|
2022-03-16 |
2024-11-01 |
Daiichi Sankyo Co Ltd |
siRNA FOR SUPPRESSING EXPRESSION OF TRANSFERRIN RECEPTOR-2
|
|
EP4495241A1
(en)
|
2022-03-16 |
2025-01-22 |
Daiichi Sankyo Company, Limited |
Chemically-modified oligonucleotide having rnai activity
|
|
WO2025047679A1
(ja)
|
2023-08-25 |
2025-03-06 |
学校法人福岡大学 |
リン酸部修飾を導入した安定型標的編集ガイドrna
|